Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse.
Saposins A, B, C and D are derived from a common precursor, prosaposin (psap). The few patients with saposin C deficiency develop a Gaucher disease-like central nervous system (CNS) phenotype attributed to diminished glucosylceramide (GC) cleavage activity by acid beta-glucosidase (GCase). The in vivo effects of saposin C were examined by creating mice with selective absence of saposin C (C-/-) using a knock-in point mutation (cysteine-to-proline) in exon 11 of the psap gene. In C-/- mice, prosaposin and saposins A, B and D proteins were present at near wild-type levels, but the saposin C protein was absent. By 1 year, the C-/- mice exhibited weakness of the hind limbs and progressive ataxia. Decreased neuromotor activity and impaired hippocampal long-term potentiation were evident. Foamy storage cells were observed in dorsal root ganglion and there was progressive loss of cerebellar Purkinje cells and atrophy of cerebellar granule cells. Ultrastructural analyses revealed inclusions in axonal processes in the spinal cord, sciatic nerve and brain, but no excess of multivesicular bodies. Activated microglial cells and astrocytes were present in thalamus, brain stem, cerebellum and spinal cord, indicating regional pro-inflammatory responses. No storage cells were found in visceral organs of these mice. The absence of saposin C led to moderate increases in GC and lactosylceramide (LacCer) and their deacylated analogues. These results support the view that saposin C has multiple roles in glycosphingolipid (GSL) catabolism as well as a prominent function in CNS and axonal integrity independent of its role as an optimizer/stabilizer of GCase.
Sun
Ying
Y
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Ran
Huimin
H
Zamzow
Matt
M
Kitatani
Kazuyuki
K
Skelton
Matthew R
MR
Williams
Michael T
MT
Vorhees
Charles V
CV
Witte
David P
DP
Hannun
Yusuf A
YA
Grabowski
Gregory A
GA
D000818:Animals; D001522:Behavior, Animal; D002490:Central Nervous System / Q000166:cytology / Q000201:enzymology / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D005776:Gaucher Disease / Q000201:enzymology / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D005962:Glucosylceramidase / Q000235:genetics / Q000378:metabolism*; D006028:Glycosphingolipids / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D011689:Purkinje Cells / Q000378:metabolism; D049231:Saposins / Q000172:deficiency*
D006028:Glycosphingolipids; D049231:Saposins; D005962:Glucosylceramidase